提供者与系统性红斑狼疮青少年对疾病活动的认知差异：一项队列研究。
Discordant Perception of Disease Activity Between Providers and Adolescents with Systemic Lupus Erythematosus: A Cohort Study.
机构信息
Department of Pediatrics, Donald and Barbara Zucker School of Medicine at Hofstra-Northwell, Hempstead, NY; Division of Pediatric Rheumatology, Cohen Children's Medical Center of NY, New Hyde Park, NY.
Department of Psychology, School of Social and Behavioral Sciences, Mercy University, Dobbs Ferry, NY.
出版信息
J Pediatr. 2024 Nov;274:114216. doi: 10.1016/j.jpeds.2024.114216. Epub 2024 Jul 27.
Abstract
Discordance in perception of disease activity between adolescent patients with lupus and their providers may influence disease outcomes. We found that patients endorsed higher perceptions of disease activity than providers. Discordance was present at all levels of disease activity, particularly in patients with high activity, nephritis, and/or taking corticosteroids or mycophenolate mofetil.
摘要
青少年狼疮患者及其提供者对疾病活动的感知不一致可能会影响疾病结局。我们发现，患者对疾病活动的感知高于提供者。在疾病活动的各个水平都存在不一致，特别是在疾病活动高、肾炎和/或服用皮质类固醇或吗替麦考酚酯的患者中。
相似文献
1
Discordant Perception of Disease Activity Between Providers and Adolescents with Systemic Lupus Erythematosus: A Cohort Study.
J Pediatr. 2024 Nov;274:114216. doi: 10.1016/j.jpeds.2024.114216. Epub 2024 Jul 27.
2
Juvenile systemic lupus erythematosus: a single-center experience from southern Turkey.
Clin Rheumatol. 2019 May;38(5):1459-1468. doi: 10.1007/s10067-019-04433-4. Epub 2019 Jan 16.
3
Mycophenolic acid exposure and complement fraction C3 influence inosine 5'-monophosphate dehydrogenase activity in systemic lupus erythematosus.
Ann Clin Biochem. 2017 Jul;54(4):490-494. doi: 10.1177/0004563216667753. Epub 2016 Aug 17.
4
Treatment of pulmonary hemorrhage in childhood systemic lupus erythematosus with mycophenolate mofetil.
South Med J. 2003 Jul;96(7):705-7. doi: 10.1097/01.SMJ.0000054424.20202.7D.
5
Outcomes following mycophenolate mofetil versus cyclophosphamide induction treatment for proliferative juvenile-onset lupus nephritis.
Lupus. 2019 Apr;28(5):613-620. doi: 10.1177/0961203319836712. Epub 2019 Mar 14.
6
Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial.
Arthritis Rheum. 2010 Jan;62(1):211-21. doi: 10.1002/art.25052.
7
Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus.
J Rheumatol. 2001 Sep;28(9):2103-8.
8
Association of systemic lupus erythematosus standard of care immunosuppressants with glucocorticoid use and disease outcomes: a multicentre cohort study.
Adv Rheumatol. 2024 May 8;64(1):38. doi: 10.1186/s42358-024-00366-y.
9
Mycophenolate Mofetil in Nonrenal Manifestations of Systemic Lupus Erythematosus: An Observational Cohort Study.
J Rheumatol. 2016 Mar;43(3):552-8. doi: 10.3899/jrheum.150779. Epub 2016 Jan 15.
10
Mycophenolate mofetil as maintenance therapy for childhood-onset systemic lupus erythematosus patients with severe lupus nephritis.
Mod Rheumatol. 2015 Mar;25(2):210-4. doi: 10.3109/14397595.2014.950810. Epub 2014 Aug 27.
本文引用的文献
1
Medication decision-making and adherence in lupus: patient-physician discordance and the impact of previous 'adverse medical experiences'.
Rheumatology (Oxford). 2022 Apr 11;61(4):1417-1429. doi: 10.1093/rheumatology/keab534.
2
Understanding patient-provider discordance in adolescents with lupus: The role of pain and antidepressant medication use.
Health Psychol Open. 2020 Dec 8;7(2):2055102920977714. doi: 10.1177/2055102920977714. eCollection 2020 Jul-Dec.
3
Determinants of Discordance Between Criteria for Inactive Disease and Low Disease Activity in Juvenile Idiopathic Arthritis.
Arthritis Care Res (Hoboken). 2021 Dec;73(12):1722-1729. doi: 10.1002/acr.24415. Epub 2021 Oct 11.
4
Patient and physician discordance of global disease assessment in juvenile dermatomyositis: findings from the Childhood Arthritis & Rheumatology Research Alliance Legacy Registry.
Pediatr Rheumatol Online J. 2020 Jan 15;18(1):5. doi: 10.1186/s12969-020-0402-x.
5
Using Clinical Characteristics and Patient-Reported Outcome Measures to Categorize Systemic Lupus Erythematosus Subtypes.
Arthritis Care Res (Hoboken). 2021 Mar;73(3):386-393. doi: 10.1002/acr.24135.
6
Discordance of patient and physician health status concerns in systemic lupus erythematosus.
Lupus. 2018 Mar;27(3):501-506. doi: 10.1177/0961203317722412. Epub 2017 Aug 1.
7
Responsiveness of the 36-item Short Form Health Survey and the Lupus Quality of Life questionnaire in SLE.
Rheumatology (Oxford). 2015 May;54(5):940-9. doi: 10.1093/rheumatology/keu410. Epub 2014 Oct 30.
8
Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus.
Arthritis Rheum. 2012 Aug;64(8):2677-86. doi: 10.1002/art.34473.
9
Prospective validation of the provisional criteria for the evaluation of response to therapy in childhood-onset systemic lupus erythematosus.
Arthritis Care Res (Hoboken). 2010 Mar;62(3):335-44. doi: 10.1002/acr.20103.
10
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.
J Clin Epidemiol. 2008 Apr;61(4):344-9. doi: 10.1016/j.jclinepi.2007.11.008.
Zotero 插件